Germany-based drug delivery systems developer AMW has signed an agreement to be acquired by a consortium led by private equity firm Yunfeng (YF) Capital and Chinese drug developer Hybio Pharmaceutical.
The deal covers AMW’s specialist pharmaceutical company located in Warngau, as well as its subsidiary Endomedica in Halle.
Go deeper with GlobalData
Founded in 2008, AMW develops, manufactures and sells advanced pharmaceutical formulations, including transdermal drug delivery systems and subcutaneous biodegradable sustained-release implants. Its products have indications in the fields of oncology, neurology, dermatology, diabetes and pain treatment.
Its portfolio includes Buprenorphine and Rivastigmin patches, along with Goserelin and Leuprorelin implants. The firm additionally has a pipeline of new products for various applications.
After the completion of the transaction, the Chinese consortium plans to support further growth of the company, invest in the development of new products and accelerate its internationalisation efforts.
Commenting on the deal, AMW managing director Wilfried Fischer said: “The commitment of the new owner to the existing product pipeline as well as the willingness to make use of the technology to start new development projects perfectly matches AMW’s long-term strategy.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHybio Pharmaceutical is a biopharmaceutical company involved in research, development, production and commercialisation of peptides and peptide-based drugs.
The acquisition forms part of the new owner’s international expansion strategy through addition of products and a research and development (R&D) pipeline.
YF Capital vice-president Albert Huang said: “Both Hybio and YF Capital intend to maintain and accelerate the growth of the company’s current structure including the transdermal and parenteral products, business sites in Warngau and Halle, as well as the skilled employees and management team.
“With the capacity of a financially strong strategic partners, we do believe that AMW can proceed to the next level in the pharma business, also we strongly believe the collaboration between AMW and Hybio will be highly beneficial for both parties, addressing global market growth opportunities.”
The new owners intend to leverage AMW’s global sales force, primarily in the US and China markets.
